Hem/Onc Roundup: COVID-19 Testing Needed for Patients with Cancer, FDA Approvals, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved various new therapies, a study assessed thyroid cancer surveillance in post-9/11 first responders, and more.

Treatment for cancer patients in the United Kingdom has been stopped or delayed due to COVID-19. In a press release, Cancer Research UK has called for widespread testing in the cancer patient population.

A new study examined whether there is a correlation between medical surveillance and incidence of post-Sept. 11, 2001, thyroid cancer among World Trade Center-exposed firefighters and emergency medical service workers. They also explored differences between asymptomatic and symptomatic cases.

The FDA approved Tukysa™ (tucatinib) in combination with trastuzumab and capecitabine for the treatment of advanced human epidermal growth factor receptor 2-positive breast cancer that is unresectible or has spread to other parts of the body, including the brain, and who have received one or more prior treatments. This is the first new drug approved under Project Orbis, an international collaboration.

The FDA approved Pemazyre™ (pemigatinib), the first targeted treatment for adults with certain types of previously treated advanced cholangiocarcinoma, a rare form of cancer that forms in bile ducts. The oral kinase inhibitor is approved for patients with tumors with the FGFR2 gene, which occur in about 9% to 14% of this patient population.

The FDA approved Trodelvy™ (sacituzumab govitecan-hziy) for patients with metastatic triple-negative breast cancer who have received at least two prior treatments.

In case you missed it, more hem/onc headlines are featured below: